The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union (EU) for paediatric patients with chronic spontaneous urticaria (CSU).
BioMarin Pharmaceutical has received the US Food and Drug Administration (FDA) approval for its supplemental biologics licence application (sBLA) for Palynziq’s (pegvaliase-pqpz) use in adolescents aged 12 and above with phenylketonuria (PKU).
Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).
IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.
Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and related comorbidities.
Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.
Beren Therapeutics has received the US Food and Drug Administration (FDA) acceptance to review its New Drug Application (NDA) for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset Niemann-Pick disease type C (NPC).
AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago site in Illinois, US.
Roche has obtained acceptance from the US Food and Drug Administration (FDA) for its new drug application (NDA) submitted for giredestrant, an oral therapy, along with everolimus to treat breast cancer.
Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.